国产一区二区三区视频精品-国产一区二区三区视频在线观看-国产一区二区三区四区五区-国产一区二区三区四区五区精品-国产一区二区三区无码免费-国产一区二区三区在线

美國BIND Therapeutics  
 BIND的生物科技是一家生物制藥公司，開發治療深刻改善集中在靶組織的藥物，同時盡量減少系統性風險患者的生活能有針對性的納米粒子。我們的技術平臺，提供了獨特的能力，為他們的特定應用優化治療精確，重復性納米我們。
　BIND公司制藥科學副總裁杰夫·哈凱基表示，這是首個進入臨床實踐的可遞送化療藥物的靶向型納米粒子。接下來，公司會將其發展成一個平臺，用于治療心血管疾病、各類炎癥，甚至傳染性疾病。


BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer.